ARYx cardiovascular, neurology, gastrointestinal news
ARYx reduced headcount to fewer than 20 and hired Cowen and Co. to explore strategic options after partnering discussions for budiodarone fell through. The anti-arrhythmic amiodarone analog has completed a Phase IIb trial to treat paroxysmal atrial fibrillation (AF). Instead of partnerships, ARYx said it will seek "near-term value" from its pipeline. The company's pipeline also includes tecarfarin, an anticoagulant that missed the primary endpoint in a Ph II/III trial to prevent blood clots last year; ATI-7505, a cisapride analog serotonin (5-HT4) receptor agonist that has completed a Phase IIb trial to treat chronic idiopathic constipation; and ATI-9242, a next-generation atypical antipsychotic agent modeled on clozapine that is in Phase I testing for schizophrenia. ...